Navigation Links
Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Date:10/8/2007

LAUSANNE, Switzerland, October 8 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented Professors Minoru Toyota and Keiichi Nakayama with the 2007 JCA-Mauvernay Award for their outstanding oncology research work. The Awards were presented during the General Assembly of the 66th Annual Conference of the JCA in Yokohama, Japan, by Professor Setsuo Hirohashi, President of the Japanese Cancer Association (JCA) and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group.

The work of Professor Toyota from the First Department of Internal Medicine, Sapporo Medical University, focuses on "DNA methylation as a new target for therapy in cancer". His applied research may lead to novel strategies for developing molecular markers and cancer therapies. DNA methylation of genes could be a useful molecular marker to predict response to chemotherapeutic drugs. The basic research work conducted by Professor Nakayama from the Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, focuses on "Ubiquitin ligases involved in cell-cycle control and cancer". His work shows that deregulation of the proteolytic system might result in uncontrolled proliferation, genomic instability and cancer. A better understanding of the ubiquitylation machinery will provide new insights into the regulatory biology of cell-cycle transitions and the development of anti-cancer drugs.

"Our goal with this Award is to recognise and reward excellent research conducted by Japanese scientists and to give them the opportunity to show their work to fellow researchers," said Kamel Besseghir, CEO of Debiopharm S.A. "This may increase the chances of their discoveries leading to the development of new medicines."

In its third year, the JCA-Mauvernay Award is organised jointly by the JCA and Debiopharm to honour innovative fundamental and clinical oncology research and to encourage Japanese scientists to make their work available outside Japan.

In August, with the Ecole Polytechnique Federale of Lausanne, Debiopharm presented the "Debiopharm Life Sciences Award" designed to mentor and motivate young innovative European researchers in the field of life sciences. Next month, the Company will reward a Chinese scientist with the "Debiopharm-CCRF China Award".

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of US$2.6 billion in 2006.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.


'/>"/>
SOURCE The Debiopharm Group
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Japanese delegates highlight Wisconsin at BIO Chicago
2. Japanese telecom opens liason office at UW-Platteville
3. Promega, Japanese lab announce partnership
4. Japanese institute installs Imago system
5. Sonic Foundry makes Japanese version of lead product
6. OpGen forges agreement with Japanese importer
7. Japanese biotech is booming and linked with Midwest
8. Japanese institute will develop for UWs Croquet platform
9. 40 Midwest biotech organizations to explore Japanese partnerships
10. Japanese Continue Relentless Biotech Stake in Midwest
11. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016 This market ... the current and future prospects of the market in ... report include companies engaged in the manufacture of microbiology ... executive summary with a market snapshot providing the overall ... of this report. This section also provides the overall ...
(Date:2/9/2016)... , February 9, 2016 Three-Year ... Enables Children to Take Part in Life-Changing Camp ... new initiative designed to positively affect the lives of children born ... care. --> SHPG ) is announcing a new initiative ... diseases, as well as the future of rare disease care. ...
(Date:2/9/2016)... LONDON , Feb. 9, 2016 /PRNewswire/ ... (PTP1B) Inhibitors-Pipeline Insights, 2016", report provides in ... their development activities around the Protein-Tyrosine Phosphatase ... the product profiles in various stages of ... Phase II, Phase III and Preregistration. Report ...
(Date:2/8/2016)... 2016 Should antibiotic bone cement products be ... prevent infection after standard total hip or knee replacement ... Institute have been fielding a lot lately. ... Line?" --> "Antibiotic Bone Cement: ... --> While there isn,t a simple answer, ...
Breaking Biology Technology:
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... Potentials of that Rising Market Are you ... new analysis forecasts revenues for checkpoint inhibitors. Visiongain,s ... world market, submarket, product and national level. ... Instead discover what progress, opportunities and revenues those ...
(Date:2/1/2016)... BURNABY, Canada , February 1, 2016 ... new technological advancements to drive global touchfree intuitive gesture ...   --> Rising sales of consumer electronics ... intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ...
(Date:1/27/2016)... 2016  Rite Track, Inc. a leading semiconductor equipment ... Chester, Ohio announced today the acquisition of PLUS ... in Austin, Texas , will significantly ... modifications, installations and technical support offerings for TEL Track ... commented, "PLUS has provided world class service including refurbishment, ...
Breaking Biology News(10 mins):